SCHEMBL16295502

SCHEMBL16295502

COc1cc(Br)c(F)cc1B(O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MAPT P10636 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
PRKDC P78527 1/20 0.40
ENPP2 Q13822 1/20 0.39
LCK P06239 1/20 0.39
FYN P06241 1/20 0.39
ALOX5 P09917 1/20 0.37
PTGS2 P35354 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37
EGFR P00533 1/20 0.36
TUBB4A P04350 3/20 0.36
TUBB P07437 3/20 0.36
TUBA3C P0DPH7 3/20 0.36
TUBA1B P68363 3/20 0.36
TUBA4A P68366 3/20 0.36
TUBB4B P68371 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954382 0.84 ENPP2 (0.45) MAPTENPP2HTR2AHTR2CEGFR
SCHEMBL1756413 0.84 ENPP2 (0.45) MAPTENPP2HTR2AHTR2CEGFR
SCHEMBL29775348 0.82 HTR2A (0.44) POLBL3MBTL1PRKDCENPP2LCK
SCHEMBL12811484 0.82 HTR2A (0.44) POLBL3MBTL1PRKDCENPP2LCK
SCHEMBL1239490 0.80 L3MBTL1 (0.69) POLBL3MBTL1MAPTNPSR1PRKDC
SCHEMBL31069479 0.80 L3MBTL1 (0.69) POLBL3MBTL1MAPTNPSR1PRKDC
SCHEMBL31085113 0.79 PRKDC (0.48) POLBL3MBTL1MAPTNPSR1PRKDC
SCHEMBL4573417 0.79 PRKDC (0.48) POLBL3MBTL1MAPTNPSR1PRKDC
SCHEMBL29126384 0.78 L3MBTL1 (0.67) POLBL3MBTL1MAPTNPSR1PRKDC
SCHEMBL26316368 0.78 ENPP2 (0.41) POLBMAPTENPP2TAAR1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9776995-B2 Bicyclic sulfonamide compounds as sodium channel inhibitors AMGEN INC. (US) 2017-10-03 US disclosed
US-9776995-B2 Bicyclic sulfonamide compounds as sodium channel inhibitors AMGEN INC. (US) 2017-10-03 US disclosed
US-9776995-B2 Bicyclic sulfonamide compounds as sodium channel inhibitors AMGEN INC. (US) 2017-10-03 US disclosed
US-20160137636-A1 Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors AMGEN INC. 2016-05-19 US disclosed
US-20160137636-A1 Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors AMGEN INC. 2016-05-19 US disclosed
US-20160137636-A1 Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors AMGEN INC. 2016-05-19 US disclosed
WO-2014201173-A1 BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS AMGEN INC. (US) 2014-12-18 WO disclosed
WO-2014201173-A1 BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS AMGEN INC. (US) 2014-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160137636-A1 Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors SCN7A, SCN1A, SCN5A POLB 4484/4885L3MBTL1 4595/4885MAPT 3282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.